These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33376084)

  • 61. Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study.
    Bellido D; Abellán P; Ruiz Palomar JM; Álvarez Sintes R; Nubiolae A; Bellido V; Romero G;
    Curr Ther Res Clin Exp; 2018; 89():37-42. PubMed ID: 30455779
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Change in HbA1c associated with treatment intensification among patients with type 2 diabetes and poor glycemic control.
    Fu AZ; Sheehan JJ
    Curr Med Res Opin; 2017 May; 33(5):853-858. PubMed ID: 28166431
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evaluating glycaemic control in patients poorly controlled on oral antidiabetic drugs in real-world setting: Results from assessing the Appropriate Timing of Type 2 diAbetes INtensification (ATTAIN).
    Jude EB; O'Leary C; Myland M; Nixon M; Gooch N; Shaunik A; Lew E
    Endocrinol Diabetes Metab; 2020 Jan; 3(1):e00094. PubMed ID: 31922021
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effectiveness of premixed insulin to achieve glycaemic control in type 2 diabetes: A retrospective UK cohort study.
    Jude EB; Trescoli C; Emral R; Ali A; Lubwama R; Palmer K; Shaunik A; Nanda N; Raskin P; Gomez-Peralta F
    Diabetes Obes Metab; 2021 Apr; 23(4):929-937. PubMed ID: 33319424
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Body weight course in the DIAbetes and LifEstyle Cohort Twente (DIALECT-1)-A 20-year observational study.
    Gant CM; Mensink I; Binnenmars SH; van der Palen JAM; Bakker SJL; Navis G; Laverman GD
    PLoS One; 2019; 14(6):e0218400. PubMed ID: 31216324
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Determinants of response to the glucagon-like peptide-1 receptor agonists in a type 2 diabetes population in the real-world.
    Franch-Nadal J; Granado-Casas M; Mata-Cases M; Ortega E; Vlacho B; Mauricio D
    Prim Care Diabetes; 2022 Dec; 16(6):810-817. PubMed ID: 36336605
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Real-World Efficacy and Safety of Dulaglutide in Korean Patients with Type 2 Diabetes Mellitus: A Retrospective Study in a Tertiary Referral Center.
    Yoon JH; Hong AR; Choi W; Park JY; Kim HK; Kang HC
    Chonnam Med J; 2021 Sep; 57(3):211-218. PubMed ID: 34621642
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Pharmaceutical therapy of diabetes mellitus type 2].
    Laubner K; Seufert J
    Internist (Berl); 2007 Mar; 48(3):297-308; quiz 309. PubMed ID: 17260149
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Real-world weight-loss effectiveness of glucagon-like peptide-1 agonists among patients with type 2 diabetes: A retrospective cohort study.
    White GE; Shu I; Rometo D; Arnold J; Korytkowski M; Luo J
    Obesity (Silver Spring); 2023 Feb; 31(2):537-544. PubMed ID: 36621904
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Impact of Glucagon-Like Peptide 1 Receptor Agonists in Patients with Hemoglobin A1c of 9% or Greater.
    Tran V; Tran H; Demirel S; Thompson-Moore N
    J Pharm Pract; 2023 Oct; 36(5):1125-1133. PubMed ID: 35427194
    [No Abstract]   [Full Text] [Related]  

  • 71. Current status of oral antidiabetic drug prescribing patterns based on the body mass index for Japanese type 2 diabetes mellitus patients and yearly changes in diabetologists' prescribing patterns from 2002 to 2019 (JDDM61).
    Yagi N; Komiya I; Arai K; Oishi M; Fukumoto Y; Shirabe S; Yokoyama H; Yamazaki K; Sugimoto H; Maegawa H;
    J Diabetes Investig; 2022 Jan; 13(1):65-73. PubMed ID: 34191401
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study.
    Aroda VR; Faurby M; Lophaven S; Noone J; Wolden ML; Lingvay I
    Diabetes Obes Metab; 2021 Sep; 23(9):2177-2182. PubMed ID: 34060209
    [TBL] [Abstract][Full Text] [Related]  

  • 73. CLINICAL CHARACTERISTICS OF PATIENTS WITH TYPE 2 DIABETES MELLITUS CONTINUED ON ORAL ANTIDIABETES MEDICATIONS IN THE HOSPITAL.
    Amir M; Sinha V; Kistangari G; Lansang MC
    Endocr Pract; 2020 Feb; 26(2):167-173. PubMed ID: 31557075
    [No Abstract]   [Full Text] [Related]  

  • 74. Discharge pharmacotherapy for Type 2 diabetic inpatients at two hospitals of different tiers in Zhejiang Province, China.
    Yu X; Zhang L; Yu R; Yang J; Zhang S
    PLoS One; 2020; 15(4):e0230123. PubMed ID: 32267843
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Developing a definition for Oral Antidiabetic Drug (OAD) Failure.
    Jindal S; Kalra S
    J Pak Med Assoc; 2020 Mar; 70(3):547-551. PubMed ID: 32207446
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Glycaemic impact of treatment intensification in patients with type 2 diabetes uncontrolled with oral antidiabetes drugs or basal insulin.
    Buysman EK; Fan T; Blauer-Peterson C; Miller-Wilson LA
    Endocrinol Diabetes Metab; 2018 Jul; 1(3):e00019. PubMed ID: 30815554
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Persistence of GLP-1 RA in combination with basal insulin among adults with type 2 diabetes in Canada.
    Abitbol A; Siemens R; Nightingale N; Stewart J; Toutounji MJ; Goldenberg R
    Diabetes Res Clin Pract; 2021 Jul; 177():108920. PubMed ID: 34139288
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Type 2 diabetics followed up by family physicians: Treatment sequences and changes over time in weight and glycated hemoglobin.
    Boullenger L; Quindroit P; Legrand B; Balcaen T; Calafiore M; Rochoy M; Beuscart JB; Chazard E
    Prim Care Diabetes; 2022 Oct; 16(5):670-676. PubMed ID: 35864077
    [TBL] [Abstract][Full Text] [Related]  

  • 79. GLP-1 Analogs Are Superior in Mediating Weight Loss But Not Glycemic Control in Diabetic Patients on Antidepressant Medications: A Retrospective Cohort Study.
    Gonzalez CL; Azim S; Miedlich SU
    Prim Care Companion CNS Disord; 2021 Sep; 23(5):. PubMed ID: 34507389
    [No Abstract]   [Full Text] [Related]  

  • 80. Assessment of Glucagon-like Peptide-1 Receptor Agonists in Veterans Taking Basal/Bolus Insulin Regimens.
    Castek SL; Healey LC; Kania DS; Vernon VP; Dawson AJ
    Fed Pract; 2022 Nov; 39(Suppl 5):S18-S23. PubMed ID: 36923548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.